About 100 reports

Inflammation of these organs can cause serious complications including heart attack, stroke and kidney failure.

  • Monoclonal Antibody
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • Fibrocell Science, Inc.

Morgan Table ##: Chemical Drugs vs.

  • Monoclonal Antibody
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Recently published study results of Xeljanz from six Phase III and two long-term extension studies reported that Xeljanz reduced the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.

  • Monoclonal Antibody
  • Market Size
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

The FDA argued that these limited clinical benefits did not outweigh the significant risk to patients, including severe high blood pressure, bleeding and hemorrhage, and heart attack or heart failure (FDA, press release, December 2010).

  • Monoclonal Antibody
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

A number of deaths have been unexplained, with a few related to heart attacks and fatal heart disruptions.

  • Monoclonal Antibody
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • Sanofi S.A.

Recently published study results of Xeljanz from six Phase III and two long-term extension studies reported that Xeljanz reduced the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.

  • Monoclonal Antibody
  • Market Size
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Galapagos NV

Side effects caused by NSAIDs incldue heartburn, stomach upset, stomach ulcers, risk of blood clots, heart attack, and stroke.

  • Monoclonal Antibody
  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Remicade group

HOWEVER, JOINT REPLACEMENT SURGERY IS ASSOCIATED WITH SIMILAR RISKS TO OTHER MAJOR SURGERIES, AS IT IS NOT IDEAL FOR OA PATIENTS AGES LESS THAN ## YEARS, DOES NOT EQUATE WITH REMISSION OR REVERSAL OF DISABILITY, AND A RECENT STUDY FOUND IT COULD INCREASE THE RISK OF HEART ATTACK (L

  • Monoclonal Antibody
  • United States
  • Ampio Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • MONOCLONAL ANTIBODIES TO INHIBIT IL-1A FOR ATHEROSCLEROSIS AND MYOCARDIAL INFARCTION - DRUG PROFILE
  • CANAKINUMAB - DRUG PROFILE

AUG ##, 2018: XBIOTECH ANNOUNCES PUBLICATION OF BREAKTHROUGH FINDINGS FOR POTENTIAL ROLE OF INTERLEUKIN-## ALPHA IN RISK FOR HEART ATTACKS XBiotech Inc., announced the publication of findings that point toward a white blood cell-derived interleukin-## alpha (IL-

  • Monoclonal Antibody
  • Therapy
  • United States
  • World
  • Product Initiative

Raloxifene is contraindicated in women who have had blood clots in their legs, lungs, or eyes, and in women who have had a heart attack or are at increased risk of a heart attack.

  • Monoclonal Antibody
  • Market Size
  • Amgen Inc.
  • Merck & Co., Inc.
  • Uni-Bio Science Group Limited

LEGAL AND REGULATORY MAR ##, 2018: ABBVIE PAYS $##M TO MAN WHO CLAIMS TESTOSTERONE DRUG CAUSED HEART ATTACK A FEDERAL JUDGE IN ILLINOIS HAS ORDERED ABBVIE TO PAY $##M AFTER A MAN CLAIMED THAT THE COMPANY' S DRUG ANDROGEL CAUSED HIM TO SUFFER A HEART ATTACK.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • United States
  • AbbVie Inc.

PEGASUS-TIMI ## was the pivotal study from which Brilinta gained regulatory approval in its indication for the long-term prevention of CV death, heart attack and stroke for patients with a history of heart attack.

  • Cell Therapy
  • Clinical Trial
  • Heart Attack
  • Monoclonal Antibody
  • World

Following its investigation into Iclusig' s safety, the FDA reported that approximately ##% of patients in the Phase II and ##% of patients in the Phase I clinical trials experienced serious adverse vascular events including heart attacks and strokes (FDA, 2013).

  • Monoclonal Antibody
  • Amgen Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

Multiple sclerosis

4385 5000 3900

These attacks could involve one location (monofocal episode) or several locations (multifocal episode) in the CNS.

  • Monoclonal Antibody
  • Europe
  • European Union
  • North America
  • United States

MACE is an umbrella term that includes heart attack, ischemic stroke, death from coronary heart disease and unstable angina requiring hospitalization.

  • Lipid Modifying Drug
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.
  • canakinumab - Drug Profile

The results of the clinical trial involving ##, ## heart attack patients showed that the drug reduced the risk of a subsequent cardiovascular event - including fatal or non-fatal heart attacks and strokes.

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Novartis AG

ANRE is a rare autoimmune disorder in which antibodies attack NMDA receptor.

  • Encephalitis
  • Infectious Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide.
  • CANAKINUMAB - DRUG PROFILE

The results of the clinical trial involving ##, ## heart attack patients showed that the drug reduced the risk of a subsequent cardiovascular event - including fatal or non-fatal heart attacks and strokes.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • Product Initiative
  • Celgene Corporation

J Heart Lung Transplant. 2009 Sep; ##(##):##-##. ##.

  • Monoclonal Antibody
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • EFFICACY OF CANAKINUMAB PRE-FILLED SYRINGES IN COMPARISON TO TRIAMCINOLONE ACETONIDE.
  • MONOCLONAL ANTIBODIES TO INHIBIT IL-1A FOR MYOCARDIAL INFARCTION AND ATHEROSCLEROSIS - DRUG PROFILE

The estimated NNT of the subgroup of patients was ##, indicating that ## patients treated with canakinumab whose hsCRP values dropped below ##mg/ L would need to be treated for five years to prevent one death, heart attack, stroke or coronary revascularization.

  • Monoclonal Antibody
  • Protein Therapy
  • Therapy
  • United States
  • Product Initiative

" WITH ROBUST REPATHA®(EVOLOCUMAB) OUTCOMES DATA, WE ARE WORKING WITH PAYERS TO IMPROVE ACCESS TO THIS IMPORTANT THERAPY FOR PATIENTS AT RISK FOR HEART ATTACKS AND STROKES. "

  • Immunotherapy
  • Monoclonal Antibody
  • United States
  • Demand
  • Amgen Inc.

In the study, a heart attack was induced in rats, which received treatment four days later, and were then assessed over a ##-day period.

  • Asthma
  • Monoclonal Antibody
  • United States
  • Company
  • AstraZeneca PLC

Annexin Pharmaceuticals reported that researchers at the University of Leiden, the Netherlands, has recently published a study showing cardio protective effect of Annexin A## in a pre-clinical model for treatment of heart attacks.

  • Monoclonal Antibody
  • Ophthalmology
  • Pharmaceutical
  • United States
  • Clearside Biomedical, Inc.

Praluent is indicated in treatment in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes.

  • Immunotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Regeneron Pharmaceuticals, Inc.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Monoclonal Antibody
  • World

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Monoclonal Antibody
  • Therapy
  • World

The trial is the largest study of allogeneic or " off the- shelf" stem cells ever conducted in heart attack patients.

  • Digestive System Disorder
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative

GammaCoeur is developed to address the need for a new cardiovascular disease risk assay and complement traditional testing methods such as total fibrinogen, cholesterol for heart attack and stroke risk.

  • Clinical Trial
  • Monoclonal Antibody
  • Sealant
  • Wound Closure
  • Cohera Medical, Inc.

Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain.

  • Chemotherapy
  • Monoclonal Antibody
  • United States
  • World
  • Product Initiative

THE STUDY WILL EVALUATE THE EFFECT OF BB## TO PRESERVE MYOCARDIAL (HEART) TISSUE AND FUNCTION FOLLOWING MYOCARDIAL INFARCTION (HEART ATTACK).

  • Health Services
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative